The objective was to identify differences in mucin expression and glycosylation between mucinous and serous type ovarian cancer of various stages and grades in order to provide a pathway, which could lead to the discovery of an effective biomarker for mucinous ovarian cancer. Here, MUC5AC is linked to mucinous ovarian cancer.